Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 34 entries
View as:

A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00717340 Org: User:
Start: 02/28/09 End: 02/28/11 Due: 02/28/12

A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01210846 Org: User:
Start: 10/31/10 End: 07/31/11 Due: 07/31/12

A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03970616 Org: User:
Start: 09/30/19 End: 04/04/23 Due: 04/04/24

A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00502307 Org: User:
Start: 10/31/07 End: 08/31/10 Due: 08/31/11

A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04100330 Org: User:
Start: 01/31/20 End: 03/27/20 Due: 03/27/21

A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT01631097 Org: User:
Start: 05/31/12 End: 01/31/14 Due: 01/31/15

A Phase 1 Study of AV-380 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04815551 Org: User:
Start: 02/22/21 End: 01/14/22 Due: 01/14/23

Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

Phase: N/A Priority: Normal
NCT ID: NCT02090127 Org: User:
Start: - End: - Due: -

An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).

Phase: N/A Priority: Normal
NCT ID: NCT01076010 Org: User:
Start: 03/31/10 End: 07/31/14 Due: 07/31/15

A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia

Phase: N/A Priority: Normal
NCT ID: NCT05865535 Org: User:
Start: 06/13/23 End: 06/30/26 Due: 06/30/27

A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01603979 Org: User:
Start: 05/31/12 End: 12/31/14 Due: 12/31/15

Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00381654 Org: User:
Start: 10/31/06 End: 02/28/10 Due: 02/28/11

A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00563147 Org: User:
Start: 11/30/07 End: 02/28/11 Due: 02/28/12

A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01363778 Org: User:
Start: 05/31/11 End: 07/31/11 Due: 07/31/12

A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01316848 Org: User:
Start: 02/28/11 End: 05/31/11 Due: 05/31/12

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06064877 Org: User:
Start: 01/11/24 End: 11/30/27 Due: 11/30/28

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04987203 Org: User:
Start: 09/09/21 End: 07/30/26 Due: 07/30/27

A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients

Phase: N/A Priority: Normal
NCT ID: NCT00551850 Org: User:
Start: 10/31/07 End: 05/31/10 Due: 05/31/11

Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers

Phase: N/A Priority: Normal
NCT ID: NCT00660153 Org: User:
Start: 06/30/08 End: 06/30/12 Due: 06/30/13

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01039948 Org: User:
Start: 12/31/09 End: 08/31/13 Due: 08/31/14

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

Phase: N/A Priority: Normal
NCT ID: NCT01369433 Org: User:
Start: 06/30/10 End: 10/31/15 Due: 10/31/16

A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01306630 Org: User:
Start: 11/30/10 End: 01/31/14 Due: 01/31/15

A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00725634 Org: User:
Start: 09/30/08 End: 12/31/13 Due: 12/31/14

A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases

Phase: N/A Priority: Normal
NCT ID: NCT00969410 Org: User:
Start: 08/31/09 End: 03/31/11 Due: 03/31/12

A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01030783 Org: User:
Start: 12/31/09 End: 06/30/13 Due: 06/30/14